ChengDa Pharmaceuticals Co. Ltd. (301201) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of ChengDa Pharmaceuticals Co. Ltd. stock ¥4.98, price ¥21.70, that is 77.1% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
ChengDa Pharmaceuticals Co. Ltd.
301201 · SHEFar too expensive (fair value 77% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
58‑month range ¥14.84 – ¥85.72 · fair‑value band ¥4.47 – ¥5.04 · the ¥21.70 price screens above the ¥4.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether ChengDa Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally.
Show moreShow less
It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate.
The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates.
ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.
Stock analysis
ChengDa Pharmaceuticals Co. Ltd. (301201) currently trades at ¥21.70, while our model-based Fair Value estimate is ¥4.98, 77% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥6.78 per share, and 0 of the 6 models we run sit above the ¥21.70 price.
Bear case: the Multiples group reads lowest at ¥1.25, and 6 of the 6 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥4.47 (bear) to ¥5.04 (bull), the price of ¥21.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
ChengDa Pharmaceuticals Co. Ltd. reported revenue of 406M CNY in FY2025 versus 416M CNY in FY2021, a compound −0.6%/yr. Reported net income was −11.9M CNY in FY2025.
Key figures
Market cap 3.4B CNY (≈ $505M) Small · P/S ratio 7.42 · EPS (TTM) ¥−0.2700 · Dividend yield 0.9% · Net margin −8.6% · Return on equity −2.0% · Return on assets (EBIT) 4.5% (5-year average) · Operating margin −7.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (medium confidence).
What moves the price
The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −77%, 301201 screens richer than that median.
Fair Value models
All 6 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
301201 screens overvalued: fair value 77% below the price. Compare with Merck KGaA →
Compare ChengDa Pharmaceuticals Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs 301201 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs 301201 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs 301201 |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs 301201 |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs 301201 |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs 301201 |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs 301201 |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs 301201 |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs 301201 |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs 301201 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ChengDa Pharmaceuticals Co. Ltd. (301201) overvalued or undervalued?
What is the fair value of 301201?
What is the quality score of 301201?
What is the price target for ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the ChengDa Pharmaceuticals Co. Ltd. stock forecast for 2026?
What is the revenue of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Does ChengDa Pharmaceuticals Co. Ltd. pay a dividend?
How much is the dividend of ChengDa Pharmaceuticals Co. Ltd. (301201) and when is the ex-dividend date?
What is the intrinsic value of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Is ChengDa Pharmaceuticals Co. Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 301201?
How much is ChengDa Pharmaceuticals Co. Ltd. worth?
What do the bullish and bearish scenarios say about 301201?
How solid is the balance sheet of ChengDa Pharmaceuticals Co. Ltd. (301201)?
How far is 301201 from its 52-week high?
Which stocks are comparable to ChengDa Pharmaceuticals Co. Ltd.?
Is ChengDa Pharmaceuticals Co. Ltd. stock attractive at the current price?
How is the fair value of 301201 calculated?
Is it still worth investing in stocks now?
What is the share price of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What should I pay attention to with ChengDa Pharmaceuticals Co. Ltd. right now?
Key figures of ChengDa Pharmaceuticals Co. Ltd.
How large is the market capitalisation of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the P/S ratio of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What are the earnings per share of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the dividend yield of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the net margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the return on equity of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the EBIT return on assets of ChengDa Pharmaceuticals Co. Ltd. (301201)?
What is the operating margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
How fast is revenue growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
How fast are earnings growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
How much free cash flow does ChengDa Pharmaceuticals Co. Ltd. (301201) generate?
How much net debt does ChengDa Pharmaceuticals Co. Ltd. (301201) carry?
Watch ChengDa Pharmaceuticals Co. Ltd. in the live analysis
One click puts ChengDa Pharmaceuticals Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.